{"id":50074,"date":"2026-08-03T20:00:00","date_gmt":"2026-08-03T18:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=ea55dfbb2a2d078ec2361d203537b382"},"modified":"2026-08-03T20:00:00","modified_gmt":"2026-08-03T18:00:00","slug":"law-offices-of-frank-r-cruz-encourages-capricor-therapeutics-inc-capr-shareholders-to-inquire-about-securities-fraud-class-action","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=50074","title":{"rendered":"Law Offices of Frank R. Cruz Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders To Inquire About Securities Fraud Class Action"},"content":{"rendered":"

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz<\/a> announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Capricor Therapeutics, Inc. (\u201cCapricor\u201d or the \u201cCompany\u201d) (NASDAQ: CAPR<\/a>) securities between December 17, 2025 and July 26, 2026<\/b>, inclusive (the \u201cClass Period\u201d). Capricor investors have until September 28, 2026 <\/b>to file a lead plaintiff motion.<\/p><\/a><\/a>

\nIF YOU SUFFERED A LOSS ON YOUR CAPRICOR INVESTMENTS, CLICK <\/b>HERE<\/b><\/a> TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.<\/b><\/p>

\nYou can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com<\/a>, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com<\/a>.<\/p>

\nWhat Happened?<\/b><\/p>

\nOn July 27, 2026, before the market opened, the U.S. Food and Drug Administration (\u201cFDA\u201d) released briefing documents ahead of its July 29 advisory committee (\u201cAdCom\u201d) meeting for the BLA. According to the briefing documents, Capricor made changes to the pre-specified statistical analysis plan (\u201cSAP\u201d) and that the final version \u201cwas not submitted to FDA for review prior to BLA submission and was not discussed and consequently not agreed upon.\u201d Critically, the final SAP was created one day before the data was unblinded. The FDA disagreed with the changes made to the SAP, stating that the \u201c<\/i><\/b>FDA does not consider the conversion of raw change to percent change and then back to raw change to have been scientifically justified, as it adds complexity and reduces accuracy.\u201d As a result, the FDA stated that it \u201cconsiders [Capricor\u2019s] analyses based on the post-study SAP versions to be post-hoc and exploratory.\u201d According to the briefing documents, \u201cthe benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness.<\/i><\/b>\u201d<\/p>

\nOn this news, Capricor\u2019s stock fell $12.70, or 64%, to close at $7.00 per share on July 27, 2026, on unusually heavy trading volume.<\/p>

\nOn July 29, 2026, the AdCom met to discuss the Deramiocel BLA. The next day, Medscape reported that the panel relied on SAP version 1.1 as the \u201cprespecified plan\u201d and, in a non-binding 9-3 vote, the panel \u201cconcluded that the available evidence does not support the efficacy of deramiocel for treating DMD-associated cardiomyopathy.\u201d<\/p>

\nOn this news, Capricor\u2019s stock fell $2.38, or 36%, to close at $4.19 per share on July 30, 2026, on unusually heavy trading volume.<\/p>

\nWhat Is The Lawsuit About?<\/b><\/p>

\nThe complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and\/or misleading statements, as well as failed to disclose material adverse facts about the Company\u2019s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel; (2) that the FDA had not agreed to those changes before the Company resubmitted the Deramiocel BLA; (3) that, as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) that, as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) that, as a result of the foregoing, Defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.<\/p>

\nContact Us To Participate or Learn More:<\/b><\/p>

\nIf you purchased Capricor securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE<\/a> or contact us at:<\/p>

\nLaw Offices of Frank R. Cruz\n2121 Avenue of the Stars, Suite 800\nCentury City, CA 90067\nTelephone: 310-914-5007\nEmail: info@frankcruzlaw.com<\/a>Visit our website at: www.frankcruzlaw.com<\/a><\/p>

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p> Contacts<\/b>

\nLaw Offices of Frank R. Cruz\n2121 Avenue of the Stars, Suite 800\nCentury City, CA 90067\nTelephone: 310-914-5007\nEmail: info@frankcruzlaw.com<\/a>Visit our website at: www.frankcruzlaw.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Capricor Therapeutics, Inc. (\u201cCapricor\u201d or the \u201cCompany\u201d) (NASDAQ: CAPR) s…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-50074","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/50074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50074"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/50074\/revisions"}],"predecessor-version":[{"id":50075,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/50074\/revisions\/50075"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}